Faron Pharmaceuticals Oy Investors - FARN

Faron Pharmaceuticals Oy Investors - FARN

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type
Faron Pharmaceuticals Oy FARN London Ordinary Share
  Price Change Price Change % Stock Price Last Trade
-2.50 -0.63% 395.00 08:15:41
Open Price Low Price High Price Close Price Previous Close
397.50 395.00 397.50 395.00 397.50
more quote information »
Industry Sector

Top Investor Posts

timbo003: Faron are presenting at the Proactive one2one investors forum this Thursday (21st January) Click here to register https://www.proactiveinvestors.co.uk/register/event_details/313
sharesoc: Potential investors and current shareholders may be interested in our webinar with Faron Pharmaceuticals (FARN), 3 November 2020 hTTps://www.sharesoc.org/events/sharesoc-webinar-with-faron-pharmaceuticals-farn-3-november-2020/
bwgs: Thank you for your reply.To date I have to say I'm very encouraged as an investor in the way Farn is moving.In respect of 3rd party funding, it may well be that Farn are being very cautious, and not willing to dilute to high heaven (which is what usually happens on AIM).Would be great to see this going back to £8+
bioking: DNL about to explode , Institutional investor added 1 million shares this week . LOTS of BIG NEWS around the corner =10+ BAGGER GEM RALLLYYYYYYYYYYYY Diurnal (DNL) Market Cap £27 M Price: 31p Upcoming Catalysts: MAA-Acceptance for Chronocort in February/March 2020 Alkindi approval in Israel expected in 2Q 2020 Alkindi approval in Australien expected in 2Q 2020 US-Partnership for Alkindi & Chronocort expected in 1H 2020 Alkindi & Chronocort Partnership for Asia für Japan und China US-Approval for Alkindi expected in 4Q 2020 EU Approval for Chronocort expected in 4Q/1Q 2020/21 Investment summary:Alkindi, a cortisol replacement therapy designed for children under 18 years of age, is DNL’s first product on the market. It is expected to be followed by Chronocort for adults – a larger market – which now has a clear pathway for regulatory approval in both Europe and the US. Despite this, the share price is still languishing well below valuations determined by peer group and DCF (202p) analyses
hashertu: DL. I think there is disappointment that the IND did not include the use of Clevegen to treat investors who suffer from refractory apathy.
daffodil4: The undisclosed investors in the latest placing presumably all took under 3%...so now they can sell on the Helsinki Nasdaq without having to declare shortly... Will those trades show on this site???? Thanks!
hashertu: I went to Proactive Investor last night. Markku (in Q&A) said that is possible that Clevegen could be available in the market as soon as 2023. I think it was said in the context of Colorectal cancer, where patients have failed all other lines of treatment, which would allow a significantly shorter approval process. I asked him about the reason for calling the EGM so soon after the recent placing, and what was referred to in the Notice, section B, "events after preparation ...". Traumakine manufacturing is the reason. At the EGM, they are seeking authority to issue 7.8m shares, and removing authority from 7.1m. Markku seemed to think it normal company practice. I have not read all the small print, but suspect that the rules governing how they can issue those shares is changed. Or more importantly, to whom. Markku is still very excited about Clevegen in his presentation. If I had to hazard a guess (Markku did not say or hint), I would say that a partner has been lined up for Clevegen. As a minimum they will take a significant stake in Faron (up to 20%) and probably pay for some/all of the Clevegen program in isolation or in combination with their own drugs. The conversations with the FDA/Traumakine/cortico steroids are quite advanced. The FDA have taken the Faron assessment of the use of CS and their effects very seriously. I got the impression that a statement was imminent. Anyway, the cash from (possible) placing might be enough to test Traumakine with CS.
dan1nat1: Lucky we didn't have a resignation then!Wichmann has a new role "Vice President, Financing and Investor Relations".His replacement "Hänninen" has come from a massive group that just so happen to be very active on the acquisition front...https://www.danaher.com/how-we-work/acquisitionsNot the time to be posting factually incorrect one line comments, based on an RNS you don't seem to understand.
bad gateway: Shame got just a few of these tucked away in case they came good but bottom of todays placing news they state that this round of funding won't be enough for 12 months (which is fair enough) and that they are looking at other sources of finance including death spiral finance. Think this shows they have no clue and pi's won't make anything here. "in addition to the Fundraise, the Company is exploring a variety of additional sources of funding and longer term funding arrangements, including discussions with potential licensees, grants, strategic investors, soft loans and an equity draw down facility. Discussions are ongoing across funding arrangements and further announcements will be made as and when required." They may not go for the equity drawdown facility (and pigs may fly) but the fact they'd even consider it makes them uninvestable from hereon in imo.
bioking: Only 31 million shares outstanding and almost 40% of these shares held by the 10 largest shareholder alone which didnt sell even after 90% drop .Stock coming from over 800p now trading at 55p .stock will rally if the Japan phase 3 results are positive which could come anytime now . Marko Salmi 3 093 439 Aviva Investors Global Services Ltd. 1 518 814 Hargreave Hale Ltd. 1 475 875 Polar Capital LLP 1 452 381 Timo Kalevi Syrjälä 1 390 830 Juho Markku Jalkanen, MD 1 082 570 Rhenman & Partners Asset Management AB 759 265 Keskinäinen Eläkevakuutusyhtiö Ilmarinen 636 721 Hargreave Hale Ltd. (Venture Capital) 167 154 Amati Global Investors Ltd. (Venture Capital) 122 993
ADVFN Advertorial
Your Recent History
Faron Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210926 10:57:16